莉芙敏治疗肾阴虚围绝经期综合征的疗效及与骨吸收水平的关系

发布时间：2018-06-03 11:45

本文选题：莉芙敏 + 围绝经期综合征　；参考：《福建中医药大学》2014年硕士论文

【摘要】：目的：本课题采用对莉英敏治疗肾阴虚围绝经期综合征的疗效分析,探讨莉芙敏对肾阴虚证型围绝经期综合征的临床治疗效果,并通过对治疗效果与血清Beta-胶原特殊序列(Beta-crosslaps, β-crosslaps)水平的相关性分析,了解莉芙敏对肾阴虚围绝经期综合征患者的疗效与骨吸收水平的关系。方法：1.研究对象：纳入符合西医围绝经期综合征诊断标准、中医肾阴虚证诊断标准并知情同意的患者,再根据排除标准及剔除标准进行筛选,最终本课题共收入肾阴虚型围绝经期综合征患者46例,其中23例为莉芙敏治疗组,另外23例为空白对照组。 2.研究方法：药物干预组予口服莉芙敏1片／次,一天2次,连续服用12周,空白对照组未予相关药物治疗。药物干预组及空白对照组在观察期间均保持生活方式基本不变。在治疗前对所收入的两组肾阴虚围绝经期综合征患者进行肾阴虚症状量化评估,测血清卵泡刺激素(Folicle stimulating hormone, FSH)、黄体生成素(Luteinizing hormone,LH)、雌二醇(Estradiol, E2)、β-crosslaps水平。在治疗后再次对所收入的两组患者进行肾阴虚症状量化评估。结果：1.肾阴虚症状积分与FSH及β-crosslaps有相关性(P0.05),均呈低度正相关(相关系数0.4)。肾阴虚症状积分与LH、E2水平无相关性(P0.05)。 2.治疗前莉芙敏治疗组与空白对照组的肾阴虚症状积分之间的差异无统计学意义(P0.05),治疗后两组间肾阴虚症状积分和疗效指数之间的差异有统计学意义(P0.05)。莉芙敏治疗组总有效率为95.65%,空白对照组总有效率为4.35%。 3.药物干预组疗效指数与β-crosslaps有相关性(P0.05),呈中度负相关(0.4相关系数0.7)。药物干预组疗效指数与FSH、LH、E2无相关性(P0.05)。 4.所有研究对象在服药期间均未出现过敏反应和其他不良反应。结论：肾阴虚症状与骨吸收水平及FSH水平呈低度正相关。莉芙敏对于肾阴虚型围绝经期综合征患者治疗效果明显,莉芙敏干预组疗效指数与β-crosslaps为中度负相关,治疗过程中未发现不良反应,临床上治疗肾阴虚围绝经期综合征患者时可选择本药,对于骨吸收水平较高的患者可考虑联合或改用其他方法治疗。
[Abstract]:Objective: to analyze the therapeutic effect of Liyingmin in the treatment of peri-menopausal syndrome of kidney yin deficiency syndrome, and to explore the clinical effect of Lifemin treatment on peri-menopausal syndrome of kidney yin deficiency syndrome. The relationship between the therapeutic effect and the serum levels of Beta-crosslaps (尾 -crosslaps) in patients with kidney yin deficiency perimenopausal syndrome and bone resorption was analyzed. Method 1: 1. Subjects: the patients who met the criteria for diagnosis of perimenopausal syndrome in Western medicine and the diagnosis criteria of deficiency of kidney yin in traditional Chinese medicine with informed consent were selected according to the criteria of exclusion and elimination. Finally, 46 cases of peri-menopausal syndrome of kidney yin deficiency type were included in this study, 23 of them were treated with Livemin and the other 23 were blank control group. 2. Methods: in the drug intervention group, one tablet was given orally, twice a day, for 12 weeks, but the blank control group was not treated with related drugs. The life style of drug intervention group and blank control group remained basically unchanged during the observation period. Before treatment, two groups of patients with kidney yin deficiency peri-menopausal syndrome were evaluated quantitatively for the symptoms of kidney yin deficiency. The serum levels of follicle stimulating hormone Folicle stimulating, FSHH, luteinizing hormone, estradiol, E2P, 尾 -crosslaps were measured. After treatment, the patients in the two groups were evaluated quantitatively for the symptoms of kidney yin deficiency. The result is 1: 1. There was a correlation between the symptom score of kidney yin deficiency and FSH and 尾 -crosslaps (P 0.05), both of which were low positive correlation (correlation coefficient 0. 4). There was no correlation between the symptom score of kidney yin deficiency and the level of LHG E 2. 2. Before treatment, there was no significant difference between Lifemin treatment group and blank control group in the symptom score of kidney yin deficiency (P 0.05), but there was significant difference between the two groups after treatment (P 0.05). The total effective rate was 95.65 in Lifemin treatment group and 4.35 in blank control group. 3. In the drug intervention group, there was a correlation between the therapeutic effect index and 尾 -crosslaps (P 0.05), with a moderate negative correlation of 0. 4 and 0. 7% (P < 0. 05). There was no correlation between the curative effect index and FSHLHN E 2 in the drug intervention group (P 0.05). 4. No allergic reactions or other adverse reactions were observed in all subjects during medication. Conclusion: there is a low correlation between kidney yin deficiency and bone resorption and FSH level. Lifmin was effective in the treatment of peri-menopausal syndrome of kidney yin deficiency type. The efficacy index of Li-min intervention group was negatively correlated with 尾 -crosslaps, and no adverse reactions were found during the treatment. In clinical treatment of kidney yin deficiency perimenopausal syndrome patients can choose this drug, for the patients with high bone resorption level may consider combining or using other treatment.
【学位授予单位】：福建中医药大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R711.75

【参考文献】